dasminapant

Generic: Dasminapant

dasminapant: 2 clinical trials tracked.

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.

BioSniper AIPage evidence connected

Prepared research question

What is verified about dasminapant, and what remains unknown?

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

An Open Label, Multiple Centers Phase Ib/II Study of APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

NCT04643405Registry updated 2026-01-08·Phase 1/Phase 2

Terminated

Primary endpoint: Dose Limiting Toxicities (DLT) of combination therapy (Applicable for: phase Ib stage ).

Interventionalopen21 targetStarted 2021-03Completion 2024-121 site · ChinaAscentage Pharma Group Inc.

A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of APG-1387 in Combination With Toripalimab in Patients With Advanced Solid Tumors

NCT04284488Registry updated 2026-01-08·Phase 1/Phase 2

Terminated

Primary endpoint: Recommended Phase 2 dose(RP2D) (Applicable for: phase I stage in various solid tumor types).

Interventionalopen40 targetStarted 2020-04Completion 2024-113 sites · ChinaAscentage Pharma Group Inc.

dasminapant evidence translation